primary focus of Lotus Pharmaceutical is addressing the fast-growing market of oncology. By aligning the company’s internal development and manufacturing capabilities, the company aims to benefit patients, its employees and shareholders alike. The company is proud of its best-in-class R&D and manufacturing platform, across Taiwan and Korea. Furthermore, Lotus Pharmaceutical can reach nearly every global market with its high value pipeline through the company’s direct markets relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

Lotus Pharmaceutical produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products, and it is these products which fuels its growth. The company offers high quality and affordable generic medications that help reduce healthcare costs for people across the globe. Lotus Pharmaceutical has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, as well as more than 250 products in the market. The product portfolio of Lotus Pharmaceutical focuses on high growth difficult-to-make generics in the fields of oncology, cardiology, nephrology and central nervous system disease.

On top of this, Lotus Pharmaceutical sells and markets a growing portfolio of OTC (over-the-counter) medicines and will be promoting the products of its partner Alvotech – a sister company in the Alvogen Group – and their biosimilar products in Asian markets once approved.

The leadership team of is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of its customers. The organisational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.